Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add filters








Language
Year range
1.
Rev. am. med. respir ; 12(4): 131-139, dic. 2012. tab
Article in Spanish | LILACS | ID: lil-667892

ABSTRACT

Objetivos: Conocer la frecuencia de Staphylococcus aureus meticilino resistente adquirido en la comunidad (SAMR-AC) en neumonía adquirida en la comunidad (NAC); examinar sus características clínicas - evolutivas y analizar factores de riesgo. Pacientes, material y métodos: Estudio retrospectivo, descriptivo, observacional, realizado en una unidad de cuidados intensivos respiratorios entre 2006 y 2012. Resultados: Se evaluaron 180 pacientes con NAC con diagnóstico etiológico. Etiologías más frecuentes: Streptococcus pneumoniae (50.5%), Haemophillus influenzae (18.3%) ySAMR-AC (12.2%, 22 casos). La neumonía por SAMR-AC se presentó en individuos jóvenes, mayoritariamente hombres. En el 81.8% de los casos el foco primario fue infección de piel y estructuras relacionadas (IPER), 95.4% presentó criterios clínicos de sepsis, 72.7% tuvo compromiso radiológico bilateral y 45.5% desarrolló derrame pleural. El 40.9% requirió ventilación mecánica y el 45.4% utilizó drogas vasoactivas. El 81.8% de los pacientes no alcanzó criterios de estabilidad clínica al cabo de la primer semana y la mortalidad fue del 36.3%, significativamente superior al resto de los microorganismos (8.8%, p<0,001). Los factores clínicos asociados con mayor riesgo de SAMR-AC fueron la presencia de IPER concomitante, compromiso radiológico bilateral, presencia de criterios clínicos de sepsis, edad inferior a 30 años y requerimiento de drogas vasoactivas. Los factores que se asociaron con mortalidad en NAC fueron la etiología por SAMR-AC y el compromiso radiológico bilateral. Conclusiones: La neumonía por SAMR-AC es una patología emergente, asociada a elevada morbimortalidad. Debe ser considerada en pacientes jóvenes, con presencia concomitante de IPER, compromiso radiológico bilateral, criterios clínicos de sepsis o necesidad de drogas vasoactivas.


Objectives: To know the incidence of Community Acquired Pneumonia (CAP) caused by Methicillin Resistant Sthaphylococcus aureus (MRSA), to examine their clinical and developmental characteristics and to analyze risk factors. Materials and Methods: Retrospective, descriptive and observational study carried out at a Respiratory Intensive Care Unit, between 2006 and 2012. Results: 180 patients with etiologic diagnosis of CAP were evaluated. The most common causes were Streptococcus pneumoniae (50.5%), Haemophillus influenzae (18.3%) and MRSA (12.2%, 22 cases). Community Acquired MRSA (CA-MRSA) pneumonia was present in young people, especially in male. In 81.8% of the cases, skin and related structure infections (SRSI) were the primary focus, 95.4% presented clinical criteria of sepsis, 72.7% had bilateral radiology involvement and 45.5% developed pleural effusion. 40.9% needed mechanical ventilation and 45.4% used vasoactive drugs. Clinical stability at the first week was not reached in 81.8% and mortality rate was 36.6%, significantly higher than for pneumonia caused by other microorganisms (8.8% p<0,001). Clinical factors related with high risk of CA-MRSA pneumonia were the concomitant presence of SRSI, bilateral radiology involvement, clinical criteria of sepsis, age <30 years old and need for vasoactive drugs. Factors related to CAP mortality were CA-MRSA aetiology and bilateral radiology involvement. Conclusions: CA-MRSA pneumonia is an emergent disease with high morbidity and mortality. It must be considered in young patients, with SRSI, bilateral radiology involvement, clinical criteria of sepsis or intake of vasoactive drugs.


Subject(s)
Humans , Adult , Community-Acquired Infections/diagnosis , Community-Acquired Infections/etiology , Staphylococcal Infections/diagnosis , Staphylococcal Infections/microbiology , Staphylococcal Infections/therapy , Pneumonia, Staphylococcal/microbiology , Methicillin-Resistant Staphylococcus aureus/isolation & purification , Anti-Bacterial Agents/administration & dosage , Cohort Studies , Risk Factors
SELECTION OF CITATIONS
SEARCH DETAIL